STOCK TITAN
  1. Home
  2. SEC Filings
  3. LYCA
  4. [Form 4] Lycia Therapeutics, Inc. Insider Trading Activity

Lycia Therapeutics: Venrock funds buy 8,305 shares

Lycia Therapeutics, Inc. (LYCA) reported an indirect purchase of 8,305 shares on November 2, 2026, by Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC and Venrock Healthcare Capital Partners EG, L.P.

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(Moderate)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. (LYCA) reported an indirect purchase of 8,305 shares on November 2, 2026, by Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC and Venrock Healthcare Capital Partners EG, L.P. The shares were purchased in multiple transactions at a weighted average price of $26.95 per share, with prices ranging from $26.60 to $27.00 inclusive. The funds reported 6,858,542 shares following the transaction; no Rule 10b5-1 plan is reported.

Insider Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Venrock Healthcare Capital Partners XP, L.P., VHCP Management XP, LLC, Koh Bong Y, Shah Nimish P
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 8,305 shs ($224K)
Increase in Position 0.12%
Type Security Shares Price Value
Purchase Common Stock F1, F2, F3, F4, F5, F6 8,305 $26.95 $224K
Holdings After Transaction: Common Stock — 6,858,542 shares (Indirect, By Funds)
Holdings Before and After: Common Stock, 6,850,237 to 6,858,542 shares (Indirect, By Funds)
Footnotes (6)
  1. F1. Consists of (i) 3,775 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 378 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 4,152 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
  2. F2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.60 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  3. F3. Consists of (i) 1,773,271 shares held by VHCP3; (ii) 177,470 shares held by VHCP Co-3; (iii) 4,256,011 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
  4. F4. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  5. F5. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  6. F6. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
Shares purchased 8,305 shares Indirect purchase on November 2, 2026
Weighted average purchase price $26.95 per share Multiple transactions on November 2, 2026
Purchase price range $26.60 to $27.00 per share Multiple transactions; inclusive
Shares following transaction 6,858,542 shares Reported post-transaction position
Shares purchased by Venrock Healthcare Capital Partners III, L.P. 3,775 shares Component of the reported purchase
Shares purchased by VHCP Co-Investment Holdings III, LLC 378 shares Component of the reported purchase
Shares purchased by Venrock Healthcare Capital Partners EG, L.P. 4,152 shares Component of the reported purchase
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficially own regulatory
"may be deemed to beneficially own the shares held by VHCP3"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
indirect pecuniary interest financial
"except to the extent of its or his indirect pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares did the Venrock funds buy, and at what price?
The funds purchased 8,305 shares on November 2, 2026, at a weighted average price of $26.95 per share. The purchases were made in multiple transactions at prices ranging from $26.60 to $27.00 inclusive; no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/02/2026P8,305(1)A$26.95(2)6,858,542(3)IBy Funds(4)(5)(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Co-Investment Holdings III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners EG, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management EG, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners XP, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management XP, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Koh Bong Y
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Shah Nimish P
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Consists of (i) 3,775 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 378 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 4,152 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.60 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
3. Consists of (i) 1,773,271 shares held by VHCP3; (ii) 177,470 shares held by VHCP Co-3; (iii) 4,256,011 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
4. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
5. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
6. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
Venrock Healthcare Capital Partners XP, L.P., By: VHCP Management XP, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
VHCP Management XP, LLC, By: /s/ Sherman G. Souther, Authorized Signatory11/04/2026
Bong Y. Koh, By: /s/ Sherman G. Souther, Attorney-in-Fact11/04/2026
Nimish P. Shah, By: /s/ Sherman G. Souther, Attorney-in-Fact11/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on LYCA

All LYCA news

Trending in the feed

MRNA
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates Open the live feed